serositis, hair loss, and easy bruising or bleeding. Her past medical history was significant for hypothyroidism, but she was not taking any medications. Family history was noncontributory. She worked as a nurse and denied any needlestick injuries or high-risk sexual behaviors. She was a former smoker without alcohol or recreational drug use. She had returned 1 week ago from Saint Lucia and recalled multiple insect bites, but no other exposures.
The patient's vital signs were within normal limits. She demonstrated mild photophobia, but lacked meningismus. She had tender anterior cervical lymphadenopathy. Her bilateral distal interphalangeal, proximal interphalangeal, metacarpal, wrist, knee, and ankle joints were tender to palpation, but did not exhibit synovitis. Active range of motion (ROM) was reduced in these joints due to pain, but passive ROM was normal. There was a faintly erythematous, maculopapular eruption over the anterior surface of both shins and circumferentially around the forearms, sparing the palms and soles. The remainder of her examination was normal.
At this point, the differential diagnosis of the patient's presentation was divided into infectious versus rheumatologic conditions. Given her recent travel and a history of insect bites, an arthropod-borne illness, such as chikungunya virus (CHIKV) or dengue virus (DENV), seemed most likely. Other infectious possibilities, considered less likely based on her history and exam, included acute human immunodeficiency virus (HIV), leptospirosis, acute mononucleosis, and acute rheumatic fever. The absence of synovitis and short duration of symptoms made rheumatologic diagnoses, such as rheumatoid arthritis (RA), systemic lupus erythematous (SLE), and post-infectious arthritis, less likely.
Laboratory tests revealed a normal complete blood count with differential, metabolic panel, liver function tests, partial thromboplastin time, international normalized ratio, thyroid stimulating hormone, and urinalysis. Chest x-ray and electrocardiogram were unremarkable. Lumbar puncture was withheld due to lack of meningismus and systemic toxicity. HIV testing was not performed as the patient lacked risk factors.
After consultation with the infectious disease service, the patient was presumptively diagnosed with CHIKV, due to her severe symmetric polyarthralgia and lack of coagulopathy, neutropenia, and thrombocytopenia, which are more common with DENV. This was further supported by her recent travel to an endemic region, where debilitating polyarthralgia has a positive predictive value of 80 % for chikungunya viremia. 1 The patient received supportive care with intravenous volume replacement and analgesics with rapid resolution of fever, rash, photophobia, myalgia, and diarrhea. Despite scheduled ibuprofen and acetaminophen, her severe polyarthralgia persisted. On hospital day 4, she was treated with methylprednisolone 40 mg with subsequent improvement in her pain. She was discharged on hospital day 6 with ibuprofen, acetaminophen, and an oral prednisone taper. After discharge, CHIKV IgM enzyme-linked immunosorbent assay (ELISA) testing returned positive; DENV testing was negative.
EPIDEMIOLOGY
Borrowed from the Kimakonde word for Bthat which bends up,^chikungunya is a RNA alpha virus of the Togaviridae family and is transmitted by the aggressive Aedes aegypti and Aedes albopictus mosquitoes. 2 Although the virus is endemic in nonhuman primates, 3 it can be transferred from human to mosquito without an animal reservoir (Fig. 1) . 4 Humans serve as the primary amplifying host, as high levels of viremia during acute illness allow for infection of biting mosquitoes. 5 CHIKV was first isolated in Tanzania in 1953, but spread to Thailand by 1958. 3 A 2004 outbreak in Kenya sparked transmission to Mozambique, India, Sri Lanka, and Southeast Asia. 4 By the end of 2005, 1.3 million cases were suspected in India after 32 years of absent disease activity. 3 Attack rates as high as 75 % were reported in some locations, such as La Réunion and Lamu Island. 3, 6 During this same outbreak, local transmission was observed for the first time in Europe, the Middle East, and Papua New Guinea. 3 CHIKV reached the Western Hemisphere in December 2013 with the first local transmission of the virus on the Caribbean island of St. Martin. 3 The virus has since spread to 44 countries and territories, including the United States, and has affected 1.2 million people ( Fig. 2 ). 7 As of February 2015, 47 states have reported a total of 2492 cases (Fig. 3 ). 8 Florida accounts for the largest number of infections, including all 11 known cases of locallytransmitted CHIKV. 9 The presence of Ae. aegypti and Ae. albopictus throughout the subtropical and temperate zones of the US suggests that the spread of CHIKV into new geographic locations is probable (Figs. 4 and 5) . 3, 6 While the CHIK V strain circulating in the Caribbean is limited in its ability to use Ae. albopictus as a vector, 3 there is the possibility of the virus establishing itself in a mosquitohuman or mosquito-vertebra cycle in the US or other parts of the Western Hemisphere.
11 Figure 1 . CHIKV is endemic in nonhuman primates, where it exists in an enzootic cycle between the animal and the Aedes mosquito. However, the virus can be transmitted to a human host via the mosquito and become established in a human-mosquito cycle without the need for an animal reservoir. 
CLINICAL MANIFESTATIONS, DIFFERENTIAL DIAG NOSIS, AND DIAGNOSIS
CHIKV infection is marked by acute onset of high fever and symmetric polyarthralgia, primarily of the small joints. 2 Fifty percent of patients will experience a non-specific maculopapular, pruritic eruption on the trunk and extremities. 2 Other symptoms include headache, myalgia, and vomiting. 5 Examination may reveal arthritis, tenosynovitis, lymphadenopathy, conjunctivitis, uveitis, and erythema of the external ear, suggestive of chondritis. 1 The most common laboratory abnormality is lymphopenia, the severity of which correlates with the degree of viremia.
1 Less frequently, thrombocytopenia, elevated transaminases, and hypocalcemia may occur in the acute infection.
1 Coagulopathy and hemorrhagic complications are exceedingly rare with CHIKV and should prompt evaluation for DENV. 1 CHIKV has an incubation period of 2-12 days, and the subsequent viremia lasts 4-6 days. 2, 12 The duration of viremia correlates both with acute illness and infectivity. 12 Acute symptoms typically resolve within 1-2 weeks, 4 but up to 60 % of patients may experience relapsing and disabling arthralgias and fatigue for months to years after the acute infection subsides. 4, 5 CHIKV has a mortality rate of less than 1 %, but vulnerable patients, such as the elderly, are at higher risk for life-threatening disease, including meningoencephalitis, myocarditis, hepatitis, or nephritis. 5 DENV, also transmitted by Aedes mosquito in the same endemic locations, is a common mimicker of CHIKV as it also causes fever and polyarthralgia. Differentiating the two viral infections can prove difficult. CHIKV is more likely to cause a severe and persistent arthralgia/arthritis, rash, and lymphopenia, whereas DENV more frequently presents with neutropenia and thrombocytopenia, and may progress to severe complications, such as hemorrhage and dengue shock syndrome (Fig. 6) . 5 It is possible for patients to be co-infected with both viruses since they share the same vector.
2,4,13 Patients suspected of either CHIKV or DENV should be tested for both viruses to rule-out coinfection. 2 Also included in the differential of CHIKVare leptospirosis, malaria, yellow fever, influenza, rickettsia, rubella, parvovirus, adenovirus, post-infectious arthritis, HIV, and rheumatologic conditions. 5,11,14 Acute CHIKV infection is suggested by
Travel-associated cases reported
Locally-acquired cases reported 10 recent travel to an endemic area followed by acute onset of severe symmetric polyarthralgia. 1 It should be noted that chronic arthralgias from CHIKV infection can mimic RA and provide a diagnostic dilemma. In a recent study, eight of ten patients with chronic symmetric polyarthritis due to CHIK V also met criteria for RA based on the 2010 American College of Rheumatology/European League Against Rheumatism criteria, highlighting the overlapping clinical features of the two diseases. 15 Although three of the eight patients had positive antinuclear antibodies, none had rheumatoid factor or anti-cyclic citrullinated protein antibodies. 15 The acute onset (within hours) of widespread severe arthralgias in CHIKV can differentiate it from RA, underscoring the importance of history in the diagnosis. 15 The number of cases of CHIKV may actually be underestimated due to the difficulty of diagnosis. The gold standard remains virus isolation, but this is seldom used. 13 During the acute phase of illness (days 1-8 from symptom onset), diagnosis can be made with reverse transcription polymerase chain reaction (RT-PCR) or IgM serology, although IgM levels may not rise until 5-7 days after the onset of symptoms. 5 In the convalescent phase (2-3 weeks after symptoms), IgG may be used to confirm the diagnosis. 2 It is recommended that both RT-PCR and serology be used to diagnose CHIKV, as false negative results are common with one test alone. 16 For patients with CHIKV meningoencephalitis, cerebrospinal fluid (CSF) typically demonstrates elevated protein levels and a pleocytosis (< 100 cells/μl) with a predominance of monocytes. 17 CHIKV RNA is not routinely detected in CSF. 17 Several laboratories in the US, including the Centers for Disease Control and Prevention (CDC), perform serology and RT-PCR testing for CHIKV, and results take 4-14 days upon receipt of the sample. 18 The CDC recommends contacting state health departments for information regarding diagnostic testing.
TREATMENT
There are no evidence-based treatment recommendations for CHIKV infection, and treatment is largely supportive with nonsteroidal anti-inflammatory drugs (NSAIDs). 19 For patients with refractory or relapsing symptoms, glucocorticoids and physical therapy have shown some benefit.
2,20 Duration of treatment is individualized to the duration of symptoms.
Current therapeutic research is targeted at the development of antivirals, monoclonal antibodies, and immunomodulatory drugs. 3 Convalescent serum from patients with previous CHIKV is able to both prevent and modify the course of the illness in mice, and a mouse monoclonal antibody has been shown to prevent viral release from cells. 21 Treatment of chronic arthralgias is challenging with the use of traditional rheumatologic agents, such as methotrexate, sulfasalazine, and chloroquine, demonstrating mixed results in both animal models and small clinical trials. 20 
IMPACT AND PREVENTION
Global travel facilitates the spread of CHIKV, and 52 % of travelers to the Caribbean have the US as their final destination. 6 Heavily populated urban centers with little immunity, coupled with the broad distribution of the mosquito vector and the high viral titers of returning infected travelers, suggest that the US is at high risk for an epidemic. 22 It is estimated that over 500 million people in the Americas are at risk of CHIKV infection, given the distribution of the virus and its vector. 23 Additionally, the impact of CHIKV outbreaks should not be underestimated as infections can quickly overwhelm health care systems and significantly impact local economies. During the La Réunion epidemic, more than 47,000 cases were diagnosed in 1 week, with the resultant loss of the ablebodied workforce requiring emergency economic rescue with crisis funding. 22 Disease prevention is the most effective method for controlling the spread of CHIKV. The Aedes species responsible for viral spread are aggressive mosquitoes, highlighting the need for protective clothing and insect repellent. 3 Keeping windows and doors closed is also protective. Patients diagnosed with CHIKV should remain indoors during the first week of acute illness, as biting mosquitoes are easily infected when high levels of viremia are present. 4, 24 Surveillance of cases, spraying for vectors, and eliminating vector breeding-sites, such as standing water, are worthwhile efforts to limit distribution of virus and vector. 22 Although no vaccine yet exists, efforts have been ongoing since the 2004 Kenyan outbreak. Antibodies derived from natural infection are believed to provide protection against future infection, and humoral immunity has been shown to protect against viremia in animal models. 25 A virus-like particle (VLP) vaccine candidate has been shown to protect nonhuman primates from infection and recently completed Phase I clinical trials. 26 Antibody development elicited by the vaccine lasted for 6 months, and concentrations at 4 weeks were similar to antibody concentrations in those with natural infection. 26 Safety data suggests that the vaccine is well-tolerated, but further research is necessary to confirm clinical efficacy. 26 
CONCLUSION
CHIKV is a global pathogen with potentially devastating economic consequences that has recently spread into the Western Hemisphere, including the US. It is crucial that the diagnosis of CHIKV be considered in patients with fever, polyarthralgia, and recent travel to endemic areas, such as the Caribbean, Central and South America, and Asia. Current treatment options are limited to supportive measures, but promising research into a vaccine is ongoing. Coordinated, prompt public health efforts will be essential in limiting the spread of CHIKV and mitigating the impact of outbreaks.
